BrightGene Bio Financials
| 688166 Stock | 30.92 1.21 4.07% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 177.2 M | 291.6 M |
|
|
BrightGene | Select Account or Indicator |
Understanding current and past BrightGene Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BrightGene Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in BrightGene Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of BrightGene Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BrightGene Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BrightGene Bio's management manipulating its earnings.
BrightGene Bio Stock Summary
BrightGene Bio competes with Guangzhou Dongfang, Tianshui Huatian, Jiujiang Shanshui, Jiangsu Financial, and GRG Banking. BrightGene Bio is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100003PR1 |
| Business Address | Building C25-28, Suzhou, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bright-gene.com |
| Phone | 86 512 6262 0988 |
You should never invest in BrightGene Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of BrightGene Stock, because this is throwing your money away. Analyzing the key information contained in BrightGene Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
BrightGene Bio Key Financial Ratios
BrightGene Bio's financial ratios allow both analysts and investors to convert raw data from BrightGene Bio's financial statements into concise, actionable information that can be used to evaluate the performance of BrightGene Bio over time and compare it to other companies across industries.| Revenue | 1.18 B | ||||
| Gross Profit | 670.14 M | ||||
| EBITDA | 264.6 M | ||||
| Net Income | 200.58 M | ||||
| Total Asset | 5.03 B |
BrightGene Bio Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.8B | 3.0B | 4.7B | 5.0B | 5.8B | 6.1B | |
| Other Current Liab | 32.0M | 25.9M | 50.7M | 20.1M | 18.1M | 26.6M | |
| Net Tangible Assets | 1.3B | 1.4B | 1.6B | 2.1B | 2.4B | 1.2B | |
| Retained Earnings | 345.5M | 555.1M | 743.4M | 830.4M | 955.0M | 1.0B | |
| Accounts Payable | 79.6M | 211.9M | 252.2M | 228.2M | 262.4M | 275.5M | |
| Cash | 339.5M | 336.8M | 1.2B | 998.0M | 1.1B | 1.2B | |
| Other Assets | 56.8M | 223.3M | 161.5M | 351.7M | 404.5M | 424.7M | |
| Net Receivables | 177.3M | 373.3M | 302.8M | 283.0M | 325.4M | 224.4M | |
| Inventory | 203.2M | 200.1M | 280.4M | 344.6M | 396.3M | 416.1M | |
| Other Current Assets | 39.6M | 73.3M | 95.4M | 65.2M | 75.0M | 49.4M | |
| Total Liab | 395.2M | 1.2B | 2.4B | 2.6B | 3.0B | 3.2B | |
| Total Current Assets | 946.4M | 993.0M | 1.9B | 1.8B | 2.1B | 1.1B | |
| Intangible Assets | 48.8M | 80.8M | 81.6M | 93.7M | 107.7M | 113.1M | |
| Net Invested Capital | 1.7B | 2.6B | 4.2B | 4.1B | 4.8B | 5.0B | |
| Net Working Capital | 654.7M | 409.9M | 1.1B | 917.5M | 1.1B | 745.5M |
BrightGene Bio Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 22.0M | 19.9M | 30.8M | 15.3M | 17.6M | 14.9M | |
| Net Interest Income | 6.3M | (10.4M) | (22.8M) | (26.7M) | (24.1M) | (22.9M) | |
| Interest Income | 9.5M | 909.7K | 2.2M | 18.0M | 20.7M | 21.7M | |
| Interest Expense | 2.0M | 9.7M | 23.7M | 44.4M | 51.1M | 53.6M | |
| Total Revenue | 785.4M | 1.1B | 1.0B | 1.2B | 1.4B | 751.2M | |
| Gross Profit | 431.4M | 591.7M | 641.0M | 658.1M | 756.8M | 438.0M | |
| Operating Income | 208.3M | 274.4M | 264.7M | 253.6M | 291.6M | 177.2M | |
| Ebit | 107.9M | 183.1M | 249.2M | 231.4M | 266.1M | 147.1M | |
| Research Development | 140.8M | 173.3M | 207.0M | 248.6M | 285.9M | 154.7M | |
| Cost Of Revenue | 354.0M | 460.7M | 376.3M | 521.4M | 599.6M | 313.2M | |
| Income Before Tax | 191.3M | 257.5M | 242.2M | 188.8M | 217.1M | 157.7M | |
| Net Income | 169.9M | 244.0M | 239.6M | 202.5M | 232.8M | 151.7M | |
| Income Tax Expense | 8.9M | 22.0M | 19.9M | 30.8M | 35.4M | 37.2M | |
| Ebitda | 146.3M | 223.6M | 308.6M | 316.4M | 363.8M | 213.0M |
BrightGene Bio Key Cash Accounts
Cash flow analysis captures how much money flows into and out of BrightGene Bio Medical. It measures of how well BrightGene is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money BrightGene Bio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money BrightGene had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what BrightGene Bio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (75.7M) | (6.3M) | (94.9M) | (85.8M) | (77.2M) | (73.3M) | |
| Investments | (218.5M) | 8.6M | (153.4M) | (445.2M) | (400.7M) | (380.6M) | |
| Change In Cash | (213.8M) | (6.3M) | 818.5M | 312.5M | 359.3M | 196.5M | |
| Depreciation | 30.2M | 41.5M | 49.9M | 78.1M | 89.8M | 94.3M | |
| Capital Expenditures | 355.3M | 909.7M | 726.7M | 389.3M | 447.7M | 371.7M | |
| Net Income | 170.1M | 243.7M | 239.6M | 200.6M | 230.7M | 151.4M | |
| End Period Cash Flow | 339.5M | 333.2M | 1.2B | 940.0M | 1.1B | 1.1B | |
| Change To Netincome | 6.9M | 17.6M | 8.6M | (4.8M) | (5.5M) | (5.2M) | |
| Free Cash Flow | (199.8M) | (733.6M) | (415.5M) | (185.1M) | (166.6M) | (174.9M) | |
| Other Non Cash Items | 22.1M | 12.3M | (3.2M) | 54.0M | 62.1M | 65.2M |
BrightGene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BrightGene Bio's current stock value. Our valuation model uses many indicators to compare BrightGene Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BrightGene Bio competition to find correlations between indicators driving BrightGene Bio's intrinsic value. More Info.BrightGene Bio Medical is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BrightGene Bio Medical is roughly 2.64 . Comparative valuation analysis is a catch-all model that can be used if you cannot value BrightGene Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BrightGene Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BrightGene Bio Medical Systematic Risk
BrightGene Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BrightGene Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on BrightGene Bio Medical correlated with the market. If Beta is less than 0 BrightGene Bio generally moves in the opposite direction as compared to the market. If BrightGene Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BrightGene Bio Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BrightGene Bio is generally in the same direction as the market. If Beta > 1 BrightGene Bio moves generally in the same direction as, but more than the movement of the benchmark.
BrightGene Bio Medical Total Assets Over Time
BrightGene Bio Thematic Clasifications
BrightGene Bio Medical is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
BrightGene Bio January 28, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BrightGene Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BrightGene Bio Medical. We use our internally-developed statistical techniques to arrive at the intrinsic value of BrightGene Bio Medical based on widely used predictive technical indicators. In general, we focus on analyzing BrightGene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BrightGene Bio's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 23.22 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 5.67 |
Complementary Tools for BrightGene Stock analysis
When running BrightGene Bio's price analysis, check to measure BrightGene Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrightGene Bio is operating at the current time. Most of BrightGene Bio's value examination focuses on studying past and present price action to predict the probability of BrightGene Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrightGene Bio's price. Additionally, you may evaluate how the addition of BrightGene Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |